|
|
|
Fig. 2. XRARα2.2 loss-of-function leads to axial truncations and reduction of HOXB9 expression. (A-D) Microinjection of RAR-MO causes anterior and posterior truncations at highest frequency when expressed in the head region (A) or dorsally (B). (C) Phenotypes are mild to undetectable when the lineage tracer is distributed laterally or ventrally. (D) Phenotypes are rescued by co-injection of XRARα2 mRNA, irrespective of where the lineage tracer is located. (E,F) Neither XBRA (E) nor XWNT8 (F) expression is affected by RAR-MO injection. (G-K) Effects of RAR-MO on the expression of HOXB9. (H-J) The types of phenotypes obtained. (K) HOXB9 expression was restored by co-injecting XRAR mRNA and RAR-MO. |
|
Display additional annotations [+]
|
|
Fig. 4. FGF8 cannot rescue the effects of XRARα2.2 loss-of-function on posterior marker genes. Embryos were microinjected at the two-cell stage with the indicated reagents, allowed to develop until controls reached stage 18 and processed for whole-mount in situ hybridization with either HOXB9 (A-E) or XCAD3 (F-J) probes. |